Moderna says commercial path remains clear despite unfavorable patent ruling

Moderna isn’t aware of any IP barriers to its products, including its COVID-19 vaccine, after a PTAB decision on Thursday shaved more than $3 billion off its market cap. The Patent Trial and Appeal Board upheld a patent owned by Arbutus that the mRNA company had sought to invalidate.

Shares of Moderna Inc. (NASDAQ:MRNA) fell $7.89 to $75.33, taking its market cap to $29.2 billion...